

# OPKO Health to Present at Upcoming September Conferences

MIAMI, Aug. 31, 2017 (GLOBE NEWSWIRE) -- **OPKO Health, Inc.** (NASDAQ:OPK) ("OPKO" or "the Company"), announces that management will present a corporate update, which will include an update on its hGH development program, at the following upcoming September 2017 investor conferences:

## 2017 Wells Fargo Healthcare Conference

Date and Time: Thursday, September 7, 2017 at 11:10 a.m. Eastern time Venue: Westin Boston Waterfront Hotel, Boston, MA Format: Company presentation

#### **Cantor Fitzgerald Global Healthcare Conference**

Date and Time: Monday, September 25, 2017 at 3:35 p.m. Eastern time Venue: InterContinental New York Barclay Hotel, New York, NY Format: Company presentation

## Ladenburg Thalmann 2017 Healthcare Conference

Date and Time: Tuesday, September 26, 2017 at 11:30 a.m. Eastern time Venue: Sofitel New York Hotel, New York, NY Format: Company presentation

#### **10th Annual Barrington Fall Investment Conference**

Date and Time: Wednesday, September 27 Venue: The Palmer House Hilton, Chicago, IL Format: One-on-One Investor Meetings

The presentations will be webcast live and can be accessed on the Investor Relations section of the Company's website at www.opko.com where they will be archived for a period of time.

## About OPKO Health, Inc.

OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI® for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and OPK88004,

an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia in phase 2a. We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at <u>www.opko.com</u>.

Contacts: Company OPKO Health, Inc. David Malina, 305-575-4100 Investor Relations dmalina@opko.com

LHA Investor Relations Anne Marie Fields, 212-838-3777 afields@lhai.com or Bruce Voss, 310-691-7100 bvoss@lhai.com



Source: OPKO Health Inc.